Irinotecan for Injection 20 mg (Irinotecan Hydrochloride SOLUTION) 20 MG

Irinotecan for Injection 20 MG is a chemotherapy medication used to treat certain types of cancer. This intravenous solution is manufactured by Teva Canada Limited and is available in 20 mg strength.

Strength

20 MG

Pack Size

2/5/25ML

Manufacturer / TM Owner

TEVA CANADA LIMITED

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Irinotecan for Injection 20 MG is primarily used in cancer treatment, often as part of a combination chemotherapy regimen. It works by interfering with the growth of cancer cells. The specific uses of Irinotecan may vary, and it is typically prescribed by healthcare professionals based on individual patient needs.

Side Effects

Common effects of Irinotecan for Injection 20 MG may include nausea, vomiting, diarrhea, and fatigue. Some patients may also experience hair loss. These effects can vary in severity and duration, and it is important to discuss any concerns with a healthcare provider.

Precautions & Warnings

Irinotecan for Injection 20 MG should be handled with care, as it is a potent medication. It is important to follow the instructions provided by a healthcare professional regarding administration and storage. Pregnant women and individuals with certain medical conditions should exercise caution and consult their healthcare provider before use.

Avoid Interactions

Irinotecan for Injection 20 MG may interact with other medications, including those that affect the liver or bone marrow. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain foods may also affect the efficacy of Irinotecan.

References

Frequently Asked Questions

Irinotecan for Injection 20 MG is used in the treatment of certain types of cancer, often as part of a combination chemotherapy regimen.

Irinotecan for Injection 20 MG is administered intravenously by a healthcare professional.

Common side effects may include nausea, vomiting, diarrhea, and fatigue. Hair loss is also a possible side effect.

Pregnant women should consult their healthcare provider before using Irinotecan for Injection 20 MG, as it may have potential risks.

It is important to follow the instructions provided by a healthcare professional regarding administration and storage. Inform your healthcare provider about all medications you are taking.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.